Northstar Group Inc. owns $357,000 in Novo Nordisk A/S (NYSE:NVO)

Northstar Group Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 10.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,000 shares of the company’s stock after selling 336 shares during the period. The holdings of Northstar Group Inc. in Novo Nordisk A/S were worth $357,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First PREMIER Bank acquired a new stake in Novo Nordisk A/S in the first quarter worth $25,000. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S in the second quarter valued at about $25,000. Dixon Mitchell Investment Counsel Inc. purchased a new stake in Novo Nordisk A/S in the 1st quarter worth about $26,000. Finally, Orion Capital Management LLC bought a new position in Novo Nordisk A/S in the first quarter valued at about $26,000. Institutional investors own 11.54% of the company’s shares.

Novo Nordisk A/S stock up 0.8%

Shares of NYSE:NVO traded up $0.90 during mid-day trading on Thursday, reaching $117.90. The company had a trading volume of 637,075 shares, compared to its average volume of 4,313,926. Novo Nordisk A/S has a 1 year low of $92.94 and a 1 year high of $148.15. The stock has a market cap of $529.08 billion, a PE ratio of 40.35, a P/E/G ratio of 1.35 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94, and a debt-to-equity ratio of 0.46. The company’s 50-day moving average price is $129.84 and its 200-day moving average price is $132.16.

Novo Nordisk A/S (NYSE:NVO – Get Free Report ) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.06). The company had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. research analysts predict that Novo Nordisk A/S will post 3.11 EPS for the current fiscal year.

Novo Nordisk A/S cuts dividends

The company also recently declared a semiannual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a $0.5126 dividend. This represents a yield of 0.7%. The ex-dividend date was Friday, August 16. Novo Nordisk A/S’s dividend payout ratio is currently 24.83%.

The Wall Street analyst weighs in

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, September 16th. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.17.

Read our latest research report on NVO

About Novo Nordisk A/S

(Free report)

Novo Nordisk A/S, together with its subsidiaries, is engaged in research and development, manufacturing and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and internationally. It operates in two segments, diabetes and obesity care and rare diseases.

Featured stories

Want to see what other hedge funds own NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).

Receive news and reviews for Novo Nordisk A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Nordisk A/S and related companies with MarketBeat.com’s FREE daily email newsletter.